“Doctor…this medicine once made the tumor shrink so much. Why is it growing again now?”

I understand how frightening this can be, especially after seeing a good response. When a tumor begins to grow again, the words “drug resistance” may sound as if every door is closing.

But resistance to one treatment does not mean resistance to every treatment—and it does not automatically mean there is no way forward.

Why Can a Treatment That Once Worked Stop Working?

A tumor is not made of identical cells. It is more like a community with many different members. Treatment may eliminate a large number of sensitive cells, while a smaller resistant population survives and later expands.

Cancer cells may alter the drug's target, activate a different growth pathway, change their cellular state, or use the tumor microenvironment to evade treatment and immune attack. Resistance can therefore be present before therapy begins or develop during treatment.

When the Cancer Starts Growing, What Should We Ask Next?

The next step is not to assume that all options are exhausted, but to reassess the situation systematically:

  • Is the cancer truly progressing, and where? Sometimes only a few sites grow while the rest of the disease remains controlled.
  • Has the biology of the cancer changed? A repeat tissue biopsy, comprehensive genomic profiling, or ctDNA testing may be considered when the result could change management.
  • Is there a new target? A new mutation, escape pathway, or biomarker may suggest sensitivity to another treatment class.
  • Should treatment be changed, combined, or directed locally? This depends on the cancer type, pattern of progression, prior therapy, and overall health.
  • Is there an appropriate clinical trial? Research studies may provide access to a new strategy for selected patients.

Medical Insight

This is the essence of precision oncology. Treatment is not chosen from the cancer's name alone. We try to understand how “today's cancer” differs from the cancer at diagnosis. Information from tissue, blood, imaging, and the previous treatment response can help guide the next sequence of care.

Genomic profiling and ctDNA are not necessary for every patient, and testing does not guarantee that an actionable treatment will be found. Each test should address a clear clinical question and be interpreted by an experienced cancer team.

If progression is limited to only one or a few sites, local treatment such as surgery or radiation may sometimes be considered while the main systemic treatment continues. In other situations, changing the drug, switching the mechanism, or using a combination may be more appropriate. There is no single answer for everyone.

What I Want You to Know

“Drug resistance” is biological information. It is not a judgment about the value of your life, and it is not your fault. You did nothing wrong.

When the original plan no longer works as before, our job is to pause, reassess, and find the next path that best fits you.

One path may aim to shrink the cancer. Another may aim to control it for as long as possible. At other times, symptom relief and quality of life may take priority. Each goal is meaningful when it is chosen together by the patient and the care team.

Take care of yourself—with care from Dr. Nine 🩷

View original Facebook post ↗Contact by email

References

  1. National Cancer Institute. Drug Resistance. View source ↗
  2. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–726. View source ↗
  3. Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020;20:743–756. View source ↗
  4. Pascual J, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer. Ann Oncol. 2022;33:750–768. View source ↗

This article provides general educational information and does not replace individualized medical assessment. Any decision to change or stop cancer treatment should be made with the treating oncology team.